Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321639087> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4321639087 endingPage "154" @default.
- W4321639087 startingPage "154" @default.
- W4321639087 abstract "154 Background: Sphingolipids are a class of bioactive signaling molecules implicated in multiple cellular processes and molecular pathways. Many publications have demonstrated that ceramides are proapoptotic, synergize with cancer treatments, and mitigate chemoresistance. Findings also demonstrated that sphingosine-1-phosphate (S1P) is a key sphingolipid that promotes cancer cell proliferation, activates multiple oncogenic pathways, and stimulates immuno-suppressor cell populations promoting a pro-tumoral microenvironment. Several studies of colorectal cancer patients have shown high levels of ceramides being associated with improved survival, while high S1P levels are associated with a poor prognosis. Hence, modulation of sphingolipid metabolism continues to be a promising treatment approach. Methods: BXQ-350 is a nanovesicle of Saposin C, an allosteric activator of sphingolipid metabolism, that lowers systemic S1P and increases C18 ceramide. BXQ-350 was investigated in a Phase 1 dose-escalation safety study in an all-comer cancer patients with advanced solid malignancies ( NCT02859857 ) to determine its safety profile and potential clinical activity as monotherapy. Samples were collected to explore potential biomarkers. Results: 13 patients (~17.8% of evaluable patients) had a clinical benefit up to cycle 6 (PR, SD), with the majority experiencing a decrease in systemic S1P levels and an increase in C18 levels. 8 patients (~11% of evaluable patients) had PFS > 6 months, with 2 patients still on study six years after enrollment. Analysis of plasma samples also revealed an increase in anti-tumoral cytokines (IFNg, TNFa, IL-2) and a decrease in pro-tumoral ones (IL-6, 8, 10). Among patients with PFS > 6 months, there were 4 recurrent CRC patients (1PR, 3SD): 1 patient had a PFS of ~12 months, 2 of ~18 months, and 1 is still on study after 6 years. Conclusions: Results of this Phase 1 study in heavily pretreated patients show BXQ-350 was well tolerated and seem to generate a clinical benefit in CRC patients via modulation of S1P and ceramides. A phase 2 trial of BXQ-350 in combination with FOLFOX/Bevacizumab in newly diagnosed mCRC is on-going with plans to further investigate this novel mechanism of action. Clinical trial information: 02859857 ." @default.
- W4321639087 created "2023-02-24" @default.
- W4321639087 creator A5003395328 @default.
- W4321639087 creator A5009849305 @default.
- W4321639087 creator A5019216768 @default.
- W4321639087 creator A5030653735 @default.
- W4321639087 creator A5037223246 @default.
- W4321639087 creator A5037535298 @default.
- W4321639087 creator A5040146841 @default.
- W4321639087 creator A5055791669 @default.
- W4321639087 creator A5058033213 @default.
- W4321639087 creator A5061224094 @default.
- W4321639087 creator A5071744643 @default.
- W4321639087 creator A5074754509 @default.
- W4321639087 date "2023-02-01" @default.
- W4321639087 modified "2023-10-16" @default.
- W4321639087 title "BXQ-350: Modulating ceramide and sphingosine-1-phosphate for antitumor activity in patients with advanced CRC." @default.
- W4321639087 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.154" @default.
- W4321639087 hasPublicationYear "2023" @default.
- W4321639087 type Work @default.
- W4321639087 citedByCount "0" @default.
- W4321639087 crossrefType "journal-article" @default.
- W4321639087 hasAuthorship W4321639087A5003395328 @default.
- W4321639087 hasAuthorship W4321639087A5009849305 @default.
- W4321639087 hasAuthorship W4321639087A5019216768 @default.
- W4321639087 hasAuthorship W4321639087A5030653735 @default.
- W4321639087 hasAuthorship W4321639087A5037223246 @default.
- W4321639087 hasAuthorship W4321639087A5037535298 @default.
- W4321639087 hasAuthorship W4321639087A5040146841 @default.
- W4321639087 hasAuthorship W4321639087A5055791669 @default.
- W4321639087 hasAuthorship W4321639087A5058033213 @default.
- W4321639087 hasAuthorship W4321639087A5061224094 @default.
- W4321639087 hasAuthorship W4321639087A5071744643 @default.
- W4321639087 hasAuthorship W4321639087A5074754509 @default.
- W4321639087 hasConcept C121608353 @default.
- W4321639087 hasConcept C126322002 @default.
- W4321639087 hasConcept C143998085 @default.
- W4321639087 hasConcept C170493617 @default.
- W4321639087 hasConcept C190283241 @default.
- W4321639087 hasConcept C2776596873 @default.
- W4321639087 hasConcept C2777550365 @default.
- W4321639087 hasConcept C2777851122 @default.
- W4321639087 hasConcept C2778703144 @default.
- W4321639087 hasConcept C502942594 @default.
- W4321639087 hasConcept C526805850 @default.
- W4321639087 hasConcept C55493867 @default.
- W4321639087 hasConcept C61705674 @default.
- W4321639087 hasConcept C71924100 @default.
- W4321639087 hasConcept C86803240 @default.
- W4321639087 hasConcept C95444343 @default.
- W4321639087 hasConcept C98274493 @default.
- W4321639087 hasConceptScore W4321639087C121608353 @default.
- W4321639087 hasConceptScore W4321639087C126322002 @default.
- W4321639087 hasConceptScore W4321639087C143998085 @default.
- W4321639087 hasConceptScore W4321639087C170493617 @default.
- W4321639087 hasConceptScore W4321639087C190283241 @default.
- W4321639087 hasConceptScore W4321639087C2776596873 @default.
- W4321639087 hasConceptScore W4321639087C2777550365 @default.
- W4321639087 hasConceptScore W4321639087C2777851122 @default.
- W4321639087 hasConceptScore W4321639087C2778703144 @default.
- W4321639087 hasConceptScore W4321639087C502942594 @default.
- W4321639087 hasConceptScore W4321639087C526805850 @default.
- W4321639087 hasConceptScore W4321639087C55493867 @default.
- W4321639087 hasConceptScore W4321639087C61705674 @default.
- W4321639087 hasConceptScore W4321639087C71924100 @default.
- W4321639087 hasConceptScore W4321639087C86803240 @default.
- W4321639087 hasConceptScore W4321639087C95444343 @default.
- W4321639087 hasConceptScore W4321639087C98274493 @default.
- W4321639087 hasIssue "4_suppl" @default.
- W4321639087 hasLocation W43216390871 @default.
- W4321639087 hasOpenAccess W4321639087 @default.
- W4321639087 hasPrimaryLocation W43216390871 @default.
- W4321639087 hasRelatedWork W114681587 @default.
- W4321639087 hasRelatedWork W1977811325 @default.
- W4321639087 hasRelatedWork W2003007879 @default.
- W4321639087 hasRelatedWork W2084654786 @default.
- W4321639087 hasRelatedWork W2112013463 @default.
- W4321639087 hasRelatedWork W2361123586 @default.
- W4321639087 hasRelatedWork W2406937849 @default.
- W4321639087 hasRelatedWork W2802746996 @default.
- W4321639087 hasRelatedWork W2897589411 @default.
- W4321639087 hasRelatedWork W4243027891 @default.
- W4321639087 hasVolume "41" @default.
- W4321639087 isParatext "false" @default.
- W4321639087 isRetracted "false" @default.
- W4321639087 workType "article" @default.